Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7217797B2 · kind B2 · utility
140Cited by
9References
50Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 15, 2003 |
| Grant date | May 15, 2007 |
| Priority date | — |
| Expiry date | Apr 7, 2024 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/732
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
The present invention provides for a modified antibody of class IgG, in which at least one amino acid from the heavy chain constant region selected from the group consisting of amino acid residues 250, 314, and 428 is substituted with another amino acid which is different from that present in the unmodified antibody, thereby altering the binding affinity for FcRn and/or the serum half-life in comparison to the unmodified antibody.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.